Sugi Predict

Sugi Predict / Targets / MAP2K5

MAP2K5

Dual specificity mitogen-activated protein kinase kinase 5 · Q13163 · MAP2K5 on Sugi Atlas →

39,658 patent compounds predicted against MAP2K5, 33,262 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL147381 SCHEMBL147381 0.50 3/20
Plx-4720 Plx-4720 (SCHEMBL133733) 1.00 2/20
SCHEMBL298368 SCHEMBL298368 0.91 2/20
SCHEMBL298198 SCHEMBL298198 0.88 2/20
SCHEMBL293053 SCHEMBL293053 0.88 2/20
SCHEMBL298626 SCHEMBL298626 0.87 2/20
SCHEMBL298282 SCHEMBL298282 0.84 2/20
SCHEMBL298379 SCHEMBL298379 0.84 2/20
SCHEMBL168511 SCHEMBL168511 0.84 2/20
SCHEMBL298349 SCHEMBL298349 0.83 2/20
SCHEMBL293377 SCHEMBL293377 0.83 2/20
SCHEMBL143765 SCHEMBL143765 0.82 2/20
SCHEMBL145998 SCHEMBL145998 0.82 2/20
SCHEMBL298613 SCHEMBL298613 0.82 2/20
SCHEMBL294160 SCHEMBL294160 0.82 2/20
SCHEMBL294126 SCHEMBL294126 0.81 2/20
SCHEMBL297768 SCHEMBL297768 0.80 2/20
SCHEMBL298366 SCHEMBL298366 0.80 2/20
SCHEMBL298547 SCHEMBL298547 0.80 2/20
SCHEMBL167615 SCHEMBL167615 0.80 2/20

Clinical trials — most relevant to MAP2K5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant PHASE2RECRUITING
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma PHASE1/PHASE2COMPLETED
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma PHASE2UNKNOWN
MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas PHASE2ACTIVE_NOT_RECRUITING
Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma PHASE2ACTIVE_NOT_RECRUITING
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy PHASE2COMPLETED
Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule PHASE2NOT_YET_RECRUITING
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... PHASE2COMPLETED
Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer PHASE2ACTIVE_NOT_RECRUITING
MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma PHASE2COMPLETED
Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M PHASE2COMPLETED
Neoadjuvant GW572016 to Treat Breast Cancer PHASE2COMPLETED
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer PHASE2COMPLETED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 PHASE1COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 PHASE1WITHDRAWN
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 PHASE1COMPLETED
Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer PHASE1COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Natural History, Pathogenesis and Outcome of Melorheostosis A Rare Osteosclerotic Disease nanRECRUITING
Identification of Novel Targetable Kinases in SR-a GvHD nanCOMPLETED
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients nanCOMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo nanUNKNOWN
Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients nanUNKNOWN
Biospecimen Collection in Assessing the Effect of Trametinib With or Without Uprosertib on Biomarkers in Patients With Persistent or Recurrent Endometrial Cancer Enrolled on Trial GOG02290 nanCOMPLETED
Molecular Phenotype Changes and Personalized Treatment for CRPC nanUNKNOWN
Molecular Analysis of Thoracic Malignancies nanENROLLING_BY_INVITATION
A Multi-omics Study of BRAF V600E Mutant Colorectal Cancer nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a MAP2K5 binder may also engage these)

ProteinNameSimilarity
Q9WVS7 — 1.000 Q9WVS7 →
Q62862 — 1.000 Q62862 →
P31938 — 0.996 P31938 →
Q07192 — 0.992 Q07192 →
Q4KSH7 — 0.990 Q4KSH7 →
Q90321 — 0.990 Q90321 →
Q90891 — 0.988 Q90891 →
Q91447 — 0.988 Q91447 →
MAP2K7 Dual specificity mitogen-activated protein kinase kinase 7 0.988 landscape →
Q63980 — 0.988 Q63980 →
A9RWC9 — 0.988 A9RWC9 →
P47809 — 0.987 P47809 →
Q9XT09 — 0.986 Q9XT09 →
Q99078 — 0.986 Q99078 →
MAP2K2 Dual specificity mitogen-activated protein kinase kinase 2 0.986 landscape →
Q1HG70 — 0.986 Q1HG70 →
MAP2K1 Dual specificity mitogen-activated protein kinase kinase 1 0.986 landscape →
P29678 — 0.985 P29678 →
Q63932 — 0.985 Q63932 →
MAP2K4 Dual specificity mitogen-activated protein kinase kinase 4 0.985 landscape →
P36506 — 0.985 P36506 →
P10506 — 0.985 P10506 →
PLK2 Serine/threonine-protein kinase PLK2 0.985 landscape →
Q9QVP9 — 0.984 Q9QVP9 →
Q9Y884 — 0.984 Q9Y884 →
Q05116 — 0.984 Q05116 →
Q5QN75 — 0.984 Q5QN75 →
Q20347 — 0.984 Q20347 →
Q5R4L1 — 0.984 Q5R4L1 →
Q01986 — 0.983 Q01986 →